Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0758
E

Failure to Manage Psychotropic Medications Appropriately

Williamsport, Pennsylvania Survey Completed on 01-24-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that a resident's medication regimen was free from potentially unnecessary medications for two residents. Resident 9 was admitted on January 16, 2023, and was receiving Buspar and Cymbalta. A consultant pharmacist recommended a dose reduction of Cymbalta from 90 mg to 60 mg on July 13, 2024, which the physician agreed to on July 24, 2024. However, the facility did not implement this change until January 17, 2025, as confirmed by the Nursing Home Administrator and Director of Nursing. Resident 65 had multiple PRN orders for Ativan, a psychotropic medication, without appropriate stop dates or evaluations by a physician to justify the extensions beyond 14 days. The facility's documentation lacked evidence of non-medicinal interventions before administering the PRN Ativan. The consultant pharmacist recommended evaluating the necessity of the PRN Ativan, but the facility's physician and contracted physician's assistant opted to continue the medication with a 90-day stop date due to ongoing anxiety, without proper documentation of behaviors or provider evaluations to justify this decision. The facility's failure to adhere to regulatory requirements for psychotropic medications resulted in deficiencies related to unnecessary drug use. The surveyor confirmed these findings with the Nursing Home Administrator and Director of Nursing, highlighting the lack of compliance with medication management protocols and the absence of necessary documentation to support the continued use of psychotropic medications for Resident 65.

Plan Of Correction

• Cited: Resident 9 and resident 65 medication regime was reviewed and properly addressed by the physician. • Like: The facility will complete a medication regime review for current residents to ensure they are free for unnecessary medications directly related to physician recommendation to decrease Cymbalta and review of PRN antianxiety medication without supporting documentation. • Education: DON/designee will educate nursing staff to ensure the pharmacist and resident 39's recommendations are followed to avoid unnecessary medications as well as recommendation to decrease Cymbalta and review of PRN anti-anxiety medications without supporting documentation. • Audits: DON/designee will audit 5 random residents weekly x 4 weeks then monthly x 2 months to ensure the pharmacist resident 39's recommendations are followed to avoid unnecessary medications. Audit will also include recommendation to decrease Cymbalta and review of PRN anti-anxiety medications without supporting documentation. Results will be taken through QAPI.

An unhandled error has occurred. Reload 🗙